Next to their role as an antidiabetic agent improving hyperglycemia in people with T2D, the SGLT2 inhibitors empagliflozin and dapagliflozin revealed a reduction in the combined risk of hospitalization or cardiovascular death in patients suffering from various types of HF with or without diabetes [26,27,28]. Here, SLC5A2 is linked to diabetes mellitus.